Literature DB >> 20855888

CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1.

Dipak Datta1, Pallavi Banerjee, Martin Gasser, Ana Maria Waaga-Gasser, Soumitro Pal.   

Abstract

The chemokine receptor CXCR3 may play a critical role in the growth and metastasis of tumor cells, including renal tumors. It has been shown that CXCR3 has two splice variants with completely opposite functions; CXCR3-A promotes cell proliferation, whereas CXCR3-B inhibits cell growth. We recently demonstrated that the expression of growth-promoting CXCR3-A is up-regulated, and the growth-inhibitory CXCR3-B is markedly down-regulated in human renal cancer tissues; and the overexpression of CXCR3-B in renal cancer cells can significantly inhibit cell proliferation. However, the growth-inhibitory signal(s) through CXCR3-B are not well characterized. Here, we investigated the effector molecule(s) involved in CXCR3-B-mediated signaling events. We found that the overexpression of CXCR3-B in human renal cancer cells (Caki-1) promoted cellular apoptosis as observed by FACS analysis through Annexin-V staining. To examine whether the overexpression of CXCR3-B could alter the expression of any apoptosis-related genes in renal cancer cells, we performed a protein array. We found that CXCR3-B overexpression significantly down-regulated the expression of antiapoptotic heme oxygenase-1 (HO-1). By utilizing a HO-1 promoter-luciferase plasmid, we showed that CXCR3-B-mediated down-regulation of HO-1 was controlled at the transcriptional level as observed by luciferase assay. We also demonstrated that the inhibition of HO-1 expression using siRNA promoted apoptosis of renal cancer cells. Finally, we observed that human renal cancer tissues expressing low amounts of CXCR3-B significantly overexpress HO-1 at both mRNA and protein level. Together, we suggest that the overexpression of CXCR3-B may prevent the growth of renal tumors through the inhibition of antiapoptotic HO-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855888      PMCID: PMC2978613          DOI: 10.1074/jbc.M110.170324

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

Review 2.  CXC chemokines: the regulatory link between inflammation and angiogenesis.

Authors:  Paola Romagnani; Laura Lasagni; Francesco Annunziato; Mario Serio; Sergio Romagnani
Journal:  Trends Immunol       Date:  2004-04       Impact factor: 16.687

3.  Involvement of chemokine receptors in breast cancer metastasis.

Authors:  A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

5.  Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase.

Authors:  F A Wagener; A Eggert; O C Boerman; W J Oyen; A Verhofstad; N G Abraham; G Adema; Y van Kooyk; T de Witte; C G Figdor
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 6.  Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment.

Authors:  J Fang; T Akaike; H Maeda
Journal:  Apoptosis       Date:  2004-01       Impact factor: 4.677

7.  A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer.

Authors:  Moulay A Alaoui-Jamali; Tarek A Bismar; Ajay Gupta; Walter A Szarek; Jie Su; Wei Song; Yingjie Xu; Bin Xu; Guoan Liu; Jason Z Vlahakis; Gheorghe Roman; Jinsong Jiao; Hyman M Schipper
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

Review 8.  Heme oxygenase-1: unleashing the protective properties of heme.

Authors:  Leo E Otterbein; Miguel P Soares; Kenichiro Yamashita; Fritz H Bach
Journal:  Trends Immunol       Date:  2003-08       Impact factor: 16.687

Review 9.  Chemokine receptors: multifaceted therapeutic targets.

Authors:  Amanda E I Proudfoot
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

10.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  29 in total

Review 1.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

2.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

3.  Small molecules in combination with conventional chemotherapeutic drugs: Light at the end of the tunnel?

Authors:  Martin Leinung; Clemens Cuny; Marc Diensthuber; Timo Stöver; Jens Wagenblast
Journal:  Oncol Lett       Date:  2012-08-28       Impact factor: 2.967

4.  Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck.

Authors:  Jens Wagenblast; Daniel Hirth; Laura Thron; Christoph Arnoldner; Marc Diensthuber; Timo Stöver; Markus Hambek
Journal:  Oncol Lett       Date:  2012-04-30       Impact factor: 2.967

5.  The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal.

Authors:  Pallavi Banerjee; Aninda Basu; Dipak Datta; Martin Gasser; Ana Maria Waaga-Gasser; Soumitro Pal
Journal:  J Biol Chem       Date:  2011-07-31       Impact factor: 5.157

Review 6.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

7.  HIV envelope protein gp120-induced apoptosis in lung microvascular endothelial cells by concerted upregulation of EMAP II and its receptor, CXCR3.

Authors:  Linden A Green; Ru Yi; Daniela Petrusca; Ting Wang; Alhasan Elghouche; Samir K Gupta; Irina Petrache; Matthias Clauss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-06       Impact factor: 5.464

8.  Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.

Authors:  Martin Leinung; Daniel Hirth; Aykut Tahtali; Marc Diensthuber; Timo Stöver; Jens Wagenblast
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

9.  A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation.

Authors:  Murugabaskar Balan; Soumitro Pal
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

Review 10.  Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

Authors:  Anup Kumar Singh; Rakesh Kumar Arya; Arun Kumar Trivedi; Sabyasachi Sanyal; Rathindranath Baral; Olivier Dormond; David M Briscoe; Dipak Datta
Journal:  Cytokine Growth Factor Rev       Date:  2012-09-16       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.